Keros Therapeutics approved a common-stock repurchase program of up to $5 million after receiving a $20 million development milestone from Takeda. The authorization matters because Keros said its cash and cash equivalents, adjusted for both items, should fund operating expenses and capital expenditures into the second half of 2028.
Key Highlights
- Keros Therapeutics had cash and cash equivalents of $257.6 million as of June 30, 2026.
- Management may repurchase common stock in the open market or through other lawful methods.
- Keros Therapeutics approved a common-stock repurchase program authorizing management to buy up to $5 million of outstanding shares.
- Repurchases may occur through open-market purchases or other methods permitted under applicable state and federal securities laws.
Keros Therapeutics, Inc. (NASDAQ: KROS) approved a common-stock repurchase program of up to $5 million, giving management authority to buy outstanding shares.
$5 Million Buyback Terms Keros’
board approved the program, which permits repurchases from time to time through open-market purchases or other methods allowed under applicable state and federal securities laws. The timing and size of any transaction will depend on the common stock’s market price, broader market and economic conditions, contractual limits and other considerations. Keros may change, suspend or end the program at any time. The authorization does not require the company to repurchase any specified dollar amount or number of shares. reported cash and cash equivalents of $257.6 million as of June 30, 2026.
FAQs
Q: What share repurchase program did Keros Therapeutics approve?
A: Keros Therapeutics approved a program for up to $5 million of its common stock. Management can conduct purchases from time to time in the open market or through other permitted methods.
Q: How could the Keros Therapeutics buyback affect investors?
A: The authorization allows Keros Therapeutics to repurchase outstanding common stock, but it does not require any purchase. Timing and transaction size will depend on market conditions and other stated factors.
Q: How much stock can Keros repurchase under the new program?
A: Keros is authorized to repurchase up to $5 million of its outstanding common stock. The authorization does not require the company to buy any specified dollar amount or number of shares.
Q: How will Keros determine the timing and size of repurchases?
A: Timing and transaction size will depend on the common stock’s market price, broader market and economic conditions, contractual limits, and other considerations.
Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research Reports
Disclaimer:
Kalkine Equities LLC, with Delaware File Number 4697384, Foreign Qualification Registration in California File Number 202109211078, and Texas File Number 805521396, is authorized to provide general advice only. The information on https://kalkine.com/ does not take into account any of your investment objectives, financial situation or needs. You should consider the appropriateness of advice taking into account your own objectives, financial situation and needs and seek independent financial advice before making any financial decisions. The link to our Terms and Conditions and Privacy Policy has been provided for your reference. On the date of publishing the reports (mentioned on the website), employees and/or associates of Kalkine do not hold positions in any of the stocks covered on the website. These stocks can change any time and readers of the reports should not consider these stocks as advice or recommendations later.